It has been 140 years since Charcot described "marked enfeeblement of the memory" with "conceptions \[that\] are formed slowly" in persons with multiple sclerosis (MS).^[@R1]^ Such cognitive symptoms were overlooked during much of the 20th century before Rao et al.^[@R2]^ brought renewed attention to MS cognitive deficits in *Neurology*® about 25 years ago, beginning a quarter century of research on the prevalence, expression, and neural bases of MS cognitive dysfunction. Current work aims to incorporate cognitive assessment into MS clinics and clinical trials, utilize state-of-the-art neuroimaging to explicate neural bases of deficits, and develop effective symptomatic cognitive treatments. First, however, key knowledge gaps require attention and methodologic approaches need improvement to advance the field toward these goals, with the ultimate goal of effective, evidence-based, clinically feasible interventions to prevent or treat cognitive deficits. Academic articles typically emphasize what is known, but awareness of the unknown provides the catalyst for scientific discovery.^e1^ As such, our international team of MS experts identified critical gaps or flaws in our knowledge and makes recommendations for future work. This is not a thorough review, but a joint statement of critical research priorities.

Cognitive dysfunction due to MS {#s1}
===============================

Cognitive profile {#s1-1}
-----------------

Slowed cognitive processing speed and episodic memory decline are the most common cognitive deficits in MS, with additional difficulties in executive function, verbal fluency, and visuospatial analysis.^[@R2][@R3][@R4]^ Anecdotally, patients often report difficulties with multitasking and word-finding, which are sorely underinvestigated. Cognitive decline often emerges early in disease,^e2−e5^ but impairment is more prevalent^e6^ and may differ qualitatively (e.g., risk for working memory deficits^e7^) among persons with progressive vs relapsing disease. Although MS leads to deficits in multiple cognitive domains on the group level,^[@R2],[@R3]^ we know little about variability in patient-level expression of cognitive deficits (e.g., patterns of isolated vs co-occurring deficits, discussed below). It is also unknown whether deficits in one cognitive domain (e.g., speed) contribute to dysfunction in other domains (e.g., memory). Although speed and memory are correlated in MS,^e8^ they are also robustly correlated in healthy persons^e9^ (likely due to general ability^e10^), so conclusions about direct links between decline in speed, memory, or any function independent of premorbid ability or disease-related mediators (e.g., cerebral atrophy) are premature and potentially misleading (i.e., may encourage unfounded expectations, e.g., that treatment of one function leads to improvement in correlated functions) (key priorities in [table 1](#T1){ref-type="table"}).
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We administer isolated cognitive tasks in rooms designed to minimize distractions; however, monotasking under ideal conditions may not capture patient-reported real-world deficits, especially in multitasking: the ubiquitous demand of young and middle adulthood to effectively manage multiple simultaneous goals (e.g., preparing dinner while having a conversation). Indeed, evidence suggests that cognition is more negatively affected in patients with MS (relative to controls) when performing cognitive tasks while walking (cognitive--motor dual task),^[@R5]^ and in the context of environmental noise (distraction).^[@R6]^ In addition to existing neuropsychological tools, the field should develop, validate, and utilize cognitive--cognitive and cognitive--motor dual-task paradigms to better address patient-reported multitasking deficits, which may be more sensitive for identifying real-world functional deficits,^e11,e12^ and also for predicting future decline.

Cognitive assessment {#s1-2}
--------------------

Cognitive processing speed is typically assessed as the amount of work performed within a time limit (e.g., number of items completed). Episodic memory is assessed as the amount of information learned and recalled (e.g., words, visual stimuli). Cognitive batteries developed for MS^[@R3],[@R7],e13^ include tests of processing speed, memory, and other functions individually administered by trained professionals. We critically reviewed the most widely used tasks ([table 2](#T2){ref-type="table"}), and identified the Symbol Digit Modalities Test (SDMT), Brief Visuospatial Memory Test-Revised (BVMT-R), and Selective Reminding Test or California Verbal Learning Test--II (CVLT-II) as the most sensitive tasks currently available for cognitive monitoring in MS. The SDMT is most sensitive, likely because good performance depends on multiple functions affected by MS (mostly processing speed, but also memory and visual scanning).^e14^ Limitations of these tasks and recommended pathways for improvements are noted in [table 1](#T1){ref-type="table"}. Patients referred for specific clinical or research questions beyond monitoring often require more comprehensive evaluations.
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Although MS batteries are brief by neuropsychological standards, the need for even 15 minutes^[@R7]^ of one-on-one testing for every patient is not practical, so cognitive monitoring is not currently part of MS standard care. Computerized testing may be a viable alternative to conventional paper-and-pencil assessment.^e19^ For instance, the Processing Speed Test (PST)^[@R8]^ is a tablet-based test modeled after the SDMT (and part of the MS Performance Test^e20^: tablet-based Multiple Sclerosis Functional Composite). Electronic data from tablet-based tasks may be integrated with electronic medical records to promote cognitive monitoring as standard care: a key innovation that would lead to (1) better detection of cognitive decline, (2) large datasets from representative samples to advance understanding of prevalence, time course, and risk factors for decline, and (3) greater feasibility of postmarket studies of disease-modifying therapy (DMT) effects on cognition.

Defining cognitive impairment {#s1-3}
-----------------------------

Cognitive tests yield quantitative values, but it is sometimes preferred to distill scores into classifications of "intact" or "impaired." Impairment is typically defined as performance below a chosen threshold (e.g., 1.5 SD below normal^[@R2],[@R3]^) but definitions of impairment have varied across studies,^e21^ affecting prevalence estimates of impairment. A large cross-sectional study of impaired performance on the Minimal Assessment of Cognitive Function in MS found that about 28%--52% of patients were impaired on tests of speed (Paced Auditory Serial Addition Test, SDMT) and 30%--55% on tests of memory (CVLT-II, BVMT-R).^[@R3]^ Rates reflect the percentage of patients impaired on each test at one time, but not the number of patients impaired (1) on composite (or latent) measures of each function (performance on single tasks is affected by multiple cognitive processes, which reduces specificity), (2) in multiple functions (deficit co-occurrence), or (3) at any point in life (lifetime prevalence). It is also unknown whether prevalence of cognitive impairment has changed quantitatively or qualitatively since the approval of newer DMT.

Studies often characterize patients as cognitively intact or impaired based on overall performance across several tests measuring different cognitive functions (e.g., failure on 3 of 11 tests^e22^), but this threshold can be met by failing speed or memory tasks alone, or a mix of speed, memory, and other tasks. This leads to heterogeneous "impaired" groups of patients with different isolated or co-occurring cognitive deficits, making interpretation of results challenging, and comparisons across studies troublesome, especially for imaging studies aiming to identify neural correlates of impairment (which likely differ across specific cognitive domains). Future work should better characterize groups as impaired in isolated or combined deficits (phenotypes, e.g., memory impaired but speed intact; speed and memory impaired), and also utilize purer measures of each cognitive domain (e.g., latent variables or composite domain scores).

Cognitive decline {#s1-4}
-----------------

When a patient reports a cognitive problem, he or she is describing a change in function from a previous level; however, the majority of cognitive research studies and clinical evaluations are cross-sectional. Clinicians and researchers examining single time points may miss decline that does not cross a given threshold for "cognitive impairment." As shown ([figure](#F1){ref-type="fig"}), patients with previous function above the 50th percentile but declining 1.5 SDs (red arrows) are not categorized as impaired, although such patients likely notice and report cognitive decline. Conversely, patients meeting criteria for impairment may experience varying degrees of decline before impairment (yellow arrows), thereby adding to heterogeneity of impaired groups. Clinically, baseline cognitive assessment in newly diagnosed patients would support accurate judgment of decline from previous function, which would be important for monitoring cognitive disability progression and potentially evaluating treatment efficacy (see discussion of regression-based norms,^[@R9]^ [links.lww.com/WNL/A185](http://links.lww.com/WNL/A185); [links.lww.com/WNL/A186](http://links.lww.com/WNL/A186)). Finally, the field requires large prospective studies with combined cognitive and MRI assessment following newly diagnosed patients (relative to controls) over many years to better understand how cognitive decline in each domain progresses. A small example of such a study was previously performed with 44 patients over 7 years.^[@R4]^

![Cognitive decline from previous functioning\
About half of persons with multiple sclerosis are considered cognitively impaired in prevalence studies, which is based on performance below a chosen threshold (yellow arrows crossing −1.5 SDs). As illustrated, however, patients may experience and report notable decline from previous function without crossing the threshold into impairment (red arrows), although such decline likely affects real-world functioning. For example, the uppermost red arrow represents a person with above average cognition prior to disease onset (84th percentile). Despite a decline of 1.5 SD, this person\'s current performance is within the average range (dark blue shaded area), and she or he would be categorized as cognitively intact in research studies. Clinically, this person may be told that he or she does not have impairment, which conflicts with his or her real experience of decline.](NEUROLOGY2017805846FF1){#F1}

Clinically meaningful change {#s1-5}
----------------------------

The Expanded Disability Status Scale^e23^ is an interval scale of physical disability in MS ranging from 0 (no disability) through 1 to 10 (0.5-point steps) reflecting disability milestones (e.g., 6.0 = unilateral gait assistance), with rubrics for clinically meaningful change.^e24^ There is no interval scale for cognition in MS, and it has been challenging to validate cognitive test score changes indicative of clinical meaningfulness^[@R10]^: an obstacle to interpretation of cognitive outcomes in prevention and treatment research. Based on work with timed ambulation metrics,^e25^ preliminary benchmarks of clinically meaningful cognitive test values^[@R11]^ or change in test values over time^[@R12]^ have been suggested (see [@R13] for SDMT), with employment status often used as an objective anchor. Ideally, we would also identify change in cognitive scores associated with cognitive difficulties in everyday life. One challenge is that patient-reported deficits and cognitive test performance are often discrepant,^e26^ which may be due in part to discrepancies between laboratory cognitive tasks and real-life cognitive demands. Note also that adequate test--retest reliability with repeated measurements^e27,e28^ is an essential and prerequisite step when validating meaningful change on cognitive tasks.

Cognitive monitoring holds promise as a useful tool for disease surveillance. Indeed, cognitive decline is associated with MRI markers of MS disease burden (see below),^[@R14]^ and cognition can be impaired even before (or without) physical disability.^e29,e30^ Emerging evidence also supports the notion of a "cognitive relapse" whereby cognitive changes may be the only behavioral indicator of disease activity (i.e., without sensorimotor symptoms).^[@R15],e31^ As such, brief cognitive monitoring tools may identify disease activity that would otherwise go untreated, and early cognitive deficits may indicate a poor prognosis for later disability and cerebral atrophy.^e32^

Neuroimaging and cognitive function {#s2}
===================================

Neuroimaging research on cognition {#s2-1}
----------------------------------

Given the essential role of MRI in MS diagnosis and disease surveillance, the field of MS is at the forefront of novel and innovative MRI technology, which provides multiple tools for investigating cognitive deficits due to MS.^[@R14]^ Cognitive deficits were linked to greater lesion load in early research,^[@R16]^ and subsequent work shows the importance of white matter lesion location,^[@R17]^ microstructural injury,^[@R18]^ gray matter lesions,^[@R19]^ cortical^[@R20]^ and subcortical^[@R21][@R22][@R23]^ gray matter brain atrophy, and discrepant patterns of cerebral activation with fMRI.^[@R24]^ Advances in ultra-high-field MRI,^e33^ myelin^e34^ and molecular^[@R25]^ imaging, imaging of demyelination and remyelination,^[@R26]^ and nonconventional MRI techniques to assess microstructural cerebral changes^[@R27]^ will provide even more ways to investigate MS-related cognitive deficits. A challenging but essential next step is to integrate rich multimodality imaging data into testable and biologically informed models of disease-related cognitive deficits, utilizing unique strengths of each imaging approach. This aspirational but critical goal will require collaboration among experts in imaging modalities, neuroscience, and cognition. Such work will inform development of biologically plausible approaches to cognitive rehabilitation (key priorities in [table 3](#T3){ref-type="table"}).
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Neural bases of cognitive deficits {#s2-2}
----------------------------------

Neuroanatomical correlates of cognitive deficits exist (e.g., thalamus^[@R21][@R22][@R23]^), but it is unclear whether such correlates (1) directly underlie deficits, or (2) are reliable proxies of overall (or other) cerebral damage, which mediate links to cognition. For instance, the thalamus is highly susceptible to retrograde degeneration,^e35^ and has better scan-to-scan reliability than other structures,^e36^ perhaps making thalamic volume a good summary measure of disease burden across patients with variable CNS damage, even if thalamic change does not directly underlie a specific deficit (e.g., memory). Although reliable correlates of cognition may be useful for prediction (discussed below), knowledge of precise neural bases is important for identifying therapeutic targets (e.g., neurotransmitter systems) for treatment of specific deficits. We need large prospective longitudinal studies with multimodality neuroimaging to carefully document temporal correlations of specific emerging cognitive deficits with changes in specific brain structures and functions, thereby informing advanced models of disease-related deficits, which will help identify therapeutic targets. For instance, longitudinal work may help substantiate cross-sectional links between memory deficits and hippocampal changes: atrophy on MRI,^[@R28]^ lesions on double inversion recovery,^[@R29]^ glutamate concentration on magnetic resonance spectroscopy,^[@R30]^ abnormal activation and functional connectivity on fMRI,^[@R31]^ and demyelination and synaptic loss on histology.^[@R32]^ (See [links.lww.com/WNL/A185](http://links.lww.com/WNL/A185) and [links.lww.com/WNL/A186](http://links.lww.com/WNL/A186) for information how segmentation of hippocampal subfields^[@R28],[@R33],[@R34]^ and thalamic nuclei^[@R35]^ may advance understanding of cognitive deficits.)

The search for specific neural correlates of distinct cognitive functions is encumbered by the imprecision of (1) heterogeneously impaired groups and (2) single cognitive tasks with multiple processing demands. MS research may be informed by lifespan research using factor analytic techniques to derive purer latent measures of speed, memory, and other functions.^[@R36]^ This approach to behavioral assessment would complement recent factor analytic MRI analyses identifying nonrandom patterns of regional cortical thinning due to MS.^[@R20]^

Quantifying risk for future cognitive decline {#s2-3}
---------------------------------------------

Longitudinal studies have linked baseline MRI to risk for cognitive decline, including T2 lesion volume, cerebral atrophy, microstructural damage, and cortical lesions.^[@R4],[@R19],[@R37]^ Although labor-intensive and expensive, we need more prospective multimodality neuroimaging studies with large representative samples to create algorithms of risk for cognitive decline. Combined with demographic, reserve,^[@R38]^ and clinical variables, such algorithms should be assessed for specificity and sensitivity in confirmation samples, thereby evaluating clinical utility. Accurate algorithms may aid in early treatment decisions (e.g., aggressiveness of DMT), and advance research and practice of early cognitive intervention. Note that clinical feasibility of MRI-informed risk algorithms is currently limited by the feasibility of employing advanced scanning sequences during clinical MRIs, as well as access to the specialty skills needed to derive quantitative MRI metrics. Indeed, even relatively basic metrics of total cerebral atrophy and T2 lesion volume are rarely available to clinicians. Different groups are working to bridge this gap by providing cerebral atrophy analysis services to clinicians, with the goal of incorporating atrophy consideration into standard clinical care.^e37^

Functional neuroimaging {#s2-4}
-----------------------

fMRI provides a proxy of brain function, which may help explain cognitive deficits due to MS.^[@R24],[@R31],[@R39],[@R40]^ There has been growing concern, however, about poor reproducibility of fMRI results, including contradictory findings of cross-sectional MS studies (e.g., memory deficits linked to lower^[@R39]^ and higher^[@R31]^ functional connectivity), and a lack of sufficiently large longitudinal studies.^[@R41]^ Inconsistencies may be due in part to differences in data collection and analysis approaches, statistical power, and heterogeneity across patient samples. There may be ways to improve the approach and consequent value of fMRI. First, reproducibility should be established with large collaborative multicenter studies using uniform methods, with out-of-sample replication of results. Next, following a model of "registered reports" in cognitive neuroscience^e38^ and trial registration ([clinicaltrials.gov](http://clinicaltrials.gov)), an online repository for posting specific study methods and hypotheses prior to data collection may be helpful. This would yield 2 levels of evidence: exploratory and confirmatory. Although exploratory research is important, certified confirmatory results would improve confidence in (1) individual study results, (2) the fMRI method in general, and (3) any future clinical utility of fMRI techniques.

Finally, it is integral that fMRI and behavioral findings be incorporated into working theoretical models of cognitive dysfunction, which will provide the scientific context for a priori hypothesis generation and testing, and model refinement. As discussed in the context of the functional reorganization hypothesis (see [@R42] and e39), such models must move beyond overly simplistic views of large network changes as either maladaptive or compensatory, and instead create more dynamic, biologically plausible models informed by multimodality neuroimaging methods.

Treatment and prevention of cognitive impairment {#s3}
================================================

Cognitive rehabilitation {#s3-1}
------------------------

Improved understanding of MS cognitive deficits will inform the nascent field of cognitive rehabilitation, which seeks to restore cognitive functioning (often through intensive cognitive training programs) or teach compensatory strategies to attenuate the deleterious effect of refractory cognitive deficits on quality of life. Efficacy for such interventions in MS is currently low, inconclusive, or preliminary, as concluded by (1) a Cochrane review of 20 randomized or quasi--randomized controlled trials (RCTs) of behavioral interventions to improve cognition in MS (data search up to July 2013),^[@R43]^ (2) a separate systematic review of 33 original intervention studies (including nonrandomized trials, search up to January 2014),^[@R44]^ and (3) a Cochrane review of 15 intervention trials specifically targeting memory (search up to June 2015).^[@R45]^ In addition to small sample sizes, quality of studies was limited by several methodologic flaws (e.g., poor blinding, unvalidated outcomes). Note also that a Cochrane review of symptomatic pharmaceutical treatment of memory deficits in MS revealed only 7 RCTs (data search up to June 2013),^[@R46]^ with no evidence for efficacy (key priorities in [table 4](#T4){ref-type="table"}).

###### 

Key priorities for treatment and prevention of cognitive deficits

![](NEUROLOGY2017805846TT4)

We require a science of cognitive rehabilitation capable of yielding high levels of evidence. Toward this end, we must develop theoretical models of MS-related cognitive dysfunction and identify mechanisms of action to treat deficits, followed by large RCTs with validated outcomes. This rigorous pathway to high-level evidence is required by regulatory agencies before approving clinical use of new agents (e.g., DMTs), and perhaps similar regulation should be considered for cognitive rehabilitation. There is less industry funding to perform large labor-intensive RCTs of cognitive rehabilitation interventions; however, grant funding may be sought for multicenter collaborations, which may increase sample size and representativeness. Finally, standards for a priori reporting of methods must be upheld for cognitive rehabilitation RCTs, including greater transparency for outcomes (e.g., specific scores on specific tests registered on [clinicaltrials.gov](http://clinicaltrials.gov), rather than nonspecific references to "cognition" or "memory tests"). Cognitive rehabilitation researchers are directed to Simons and colleagues^[@R47]^ for a thorough discussion of essential guidelines for the conduct of high-quality cognitive intervention trials.

Theoretical models {#s3-2}
------------------

As proposed for the field of rehabilitation generally,^[@R48]^ we must identify mechanisms of action and active ingredients of cognitive rehabilitation interventions. For instance, if we discover that a training program improves memory by strengthening hippocampal structure and function, we may also consider other interventions targeting hippocampal health; e.g., aerobic exercise,^e40^ intellectual enrichment,^e41^ glucose control,^e42^ and stress management.^e43^ Availability of alternative treatments is important when considering clinical feasibility, as time-consuming, expensive cognitive training programs may be feasible for some patients, whereas other patients will be more likely to engage in alternative approaches (e.g., exercise). A model should also distinguish different types of rehabilitation approaches and goals: (1) restorative interventions aiming to bolster underlying neurophysiologic bases of memory, vs (2) compensatory approaches aiming to improve memory through strategies (e.g., mnemonics) or aids (e.g., diaries; see discussion^e44,e45^). This has implications for trial outcomes: e.g., given that compensatory strategies only work when patients use them (like a cane for walking), we should not assess treatment efficacy with standardized memory tests that prevent or encumber strategy usage (as standardized administrations may prevent compensatory strategy usage).

Secondary structural and functional neuroimaging outcomes may help identify mechanisms of action for interventions^[@R49]^ and identify markers of capacity to benefit from interventions (responders vs nonresponders). This may help hone treatments and inform new treatment development, and identify subgroups with residual capacity to respond to interventions. Like cognitive outcomes, specific neuroimaging outcomes should be stated (registered) prior to data collection, or otherwise be described as exploratory. Finally, the goal of enhancing brain structure and function in biologically plausible and lasting ways likely requires greater "doses" (duration and intensity) of interventions than is typically performed, and perhaps combined therapies with potentially synergistic effects (e.g., training plus neurostimulation^e46^).

Primary prevention {#s3-3}
------------------

We should also promote primary prevention of cognitive decline, in part through interventions and healthy lifestyles that promote brain maintenance.^[@R50],[@R51]^ Candidate modifiable lifestyle factors to build or maintain brain reserve include physical exercise,^[@R52]^ mentally active lifestyles (cognitive reserve),^[@R38],[@R53]^ management of cardiovascular risk factors^[@R54]^ and other comorbidities,^[@R55]^ smoking cessation,^[@R56]^ and stress management.^[@R57]^ Research should strive to understand mechanisms of action for protective factors (e.g., moderating MS disease activity vs maintaining brain volume in a non-disease-specific way). Studies typically examine few risk or protective factors at a time, but we need larger studies of numerous factors in the same large cohort to understand (1) whether and to what extent each risk or protective factor makes independent contributions to an outcome, (2) mediating or interactive effects among different factors on an outcome, and (3) how (1) and (2) differ across outcomes (e.g., speed, memory). We also need to raise the level of evidence (e.g., RCTs) linking lifestyle factors to cognition, and explore additional variables (e.g., diet^e47,e48^). (DMTs as protective factors are discussed in [links.lww.com/WNL/A185](http://links.lww.com/WNL/A185) and [links.lww.com/WNL/A186](http://links.lww.com/WNL/A186).)

Holistic approach to cognitive rehabilitation {#s3-4}
---------------------------------------------

Effective intervention will require patient understanding, motivation, and compliance, as well as willingness by clinicians to consider the unique circumstances of individual patients (e.g., family/social support, comorbidities, goals). Ideal holistic rehabilitation approaches consider cognitive, emotional, and psychosocial aspects of each patient\'s life.^[@R58]^ Patient education may promote metacognition and active participation. For instance, therapeutic feedback after neuropsychological assessments may support understanding of one\'s cognitive profile, and aid patients in finding ways to maximize cognitive strengths and minimize weaknesses in daily life. Education on cognitive deficits and factors affecting cognition (e.g., sleep, medications, mood, fatigue) may promote active participation and a positive sense of agency among patients.^[@R59]^ Indeed, preliminary results on structured metacognitive training with peer support are encouraging.^e49^ To advance this holistic approach, research is also needed to better understand shared neural bases for mood and cognitive dysfunction,^[@R60]^ which may yield new directions for cognitive treatments. Finally, treatment will likely be most effective when tailored to a patient\'s specific deficit in the context of his or her degree of spared cognition and cerebral reserve. For instance, a memory deficit due to diffuse white matter lesions may require a different treatment approach than a deficit secondary to a focal hippocampal lesion. Consideration of distinct subtypes of deficits requiring distinct treatment approaches (i.e., precision medicine) is a key challenge and opportunity for the future.

Discussion {#s4}
==========

The literature on cognition in persons with MS has grown exponentially over the last 25 years, and cognitive dysfunction is now recognized as a core symptom of MS. Herein we discussed obstacles and challenges for the field and made recommendations for moving research forward. The next 25 years will bring redoubled collaboration across centers and areas of expertise, and utilize advances in neuroimaging, genetics/epigenetics, and validation of cognitive endpoints. Collaborations and advanced methods are invaluable, but the real science of cognition and cognitive rehabilitation in MS will rely on multidisciplinary collaborations toward development of biologically based theoretical models of cognition capable of empirical validation and evidence-based refinement, providing the necessary context for effective treatment discovery.
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